ORGANIZATION

• IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
  July 31, 2023

• Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
  July 24, 2023

• JPA to Issue Policy Proposal to Address Lingering Supply Crisis
  July 24, 2023

• More People Seek Self-Medication Tax Break in 2022
  July 24, 2023

• JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
  July 21, 2023

• Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
  July 21, 2023

• Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
  July 20, 2023

• Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
  July 19, 2023

• Reform Regenerative Medicine Systems to Fight Lag, Loss: FIRM to Japan Govt
  July 12, 2023

• Stop Requiring Japanese PI Data for Global Products: JPMA Officials
  July 10, 2023

• PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
  July 4, 2023

• Generic Use Rate at 80.7% in FY2022: JGA
  June 30, 2023

• Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
  June 27, 2023

• FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
  June 26, 2023

• New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
  June 23, 2023

• FPMAJ Makes 1st Update for Generic Supply Guidelines in 9 Years
  June 22, 2023

• Patient Group Requests Early Approval of New ALS Drugs in Japan
  June 22, 2023

• Astellas’ Yoshitsugu Shitaka Elected as New FIRM Chair
  June 20, 2023

• Lag and Loss Blamed on Drug Pricing System, JPMA Set to Get Involved in Corrective Steps: President
  June 15, 2023

• Over 70% of Pharmacies Fill “Zero” Refill Prescriptions per Month: FPMAJ Survey
  June 13, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• …
• Next ›
• 最終 »